JP2018536621A5 - - Google Patents

Download PDF

Info

Publication number
JP2018536621A5
JP2018536621A5 JP2018511684A JP2018511684A JP2018536621A5 JP 2018536621 A5 JP2018536621 A5 JP 2018536621A5 JP 2018511684 A JP2018511684 A JP 2018511684A JP 2018511684 A JP2018511684 A JP 2018511684A JP 2018536621 A5 JP2018536621 A5 JP 2018536621A5
Authority
JP
Japan
Prior art keywords
independently
xaa
cancer
macrocycle
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018511684A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536621A (ja
JP6971970B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/050194 external-priority patent/WO2017040990A1/en
Publication of JP2018536621A publication Critical patent/JP2018536621A/ja
Publication of JP2018536621A5 publication Critical patent/JP2018536621A5/ja
Application granted granted Critical
Publication of JP6971970B2 publication Critical patent/JP6971970B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018511684A 2015-09-03 2016-09-02 ペプチド模倣大環状分子およびその使用 Expired - Fee Related JP6971970B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562214142P 2015-09-03 2015-09-03
US62/214,142 2015-09-03
US201662310254P 2016-03-18 2016-03-18
US62/310,254 2016-03-18
US201662344791P 2016-06-02 2016-06-02
US201662344651P 2016-06-02 2016-06-02
US62/344,651 2016-06-02
US62/344,791 2016-06-02
PCT/US2016/050194 WO2017040990A1 (en) 2015-09-03 2016-09-02 Peptidomimetic macrocycles and uses thereof

Publications (3)

Publication Number Publication Date
JP2018536621A JP2018536621A (ja) 2018-12-13
JP2018536621A5 true JP2018536621A5 (https=) 2019-10-17
JP6971970B2 JP6971970B2 (ja) 2021-11-24

Family

ID=58188595

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018511684A Expired - Fee Related JP6971970B2 (ja) 2015-09-03 2016-09-02 ペプチド模倣大環状分子およびその使用

Country Status (11)

Country Link
US (2) US20170114098A1 (https=)
EP (1) EP3344275B8 (https=)
JP (1) JP6971970B2 (https=)
KR (1) KR20180043835A (https=)
CN (1) CN108348571B (https=)
AU (1) AU2016315878A1 (https=)
BR (1) BR112018003985A2 (https=)
CA (1) CA2996685A1 (https=)
IL (1) IL257706A (https=)
MX (1) MX2018002723A (https=)
WO (1) WO2017040990A1 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105061577A (zh) 2006-12-14 2015-11-18 爱勒让治疗公司 双巯基大环化系统
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ES2398310T3 (es) 2007-02-23 2013-03-15 Aileron Therapeutics, Inc. Péptidos macrocíclicos unidos a triazol
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
WO2010083347A2 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20130072439A1 (en) 2009-09-22 2013-03-21 Huw M. Nash Peptidomimetic macrocycles
KR20170058446A (ko) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
SG11201702175YA (en) 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
WO2016049359A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. Mcl−1のモジュレーターとしてのペプチド模倣大環状分子
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
US20190240210A1 (en) * 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
EP3532464A4 (en) 2016-10-28 2020-07-08 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER
JP2020514252A (ja) 2016-12-08 2020-05-21 アイカーン スクール オブ メディスン アット マウント シナイ Cdk4/6媒介性がんを治療するための組成物および方法
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
US20180371021A1 (en) * 2017-05-11 2018-12-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US11566073B2 (en) 2017-06-01 2023-01-31 Bristol-Myers Squibb Company Methods of treating a tumor using an anti-PD-1 antibody
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
CA3092677A1 (en) 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
CA3104298A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
WO2020023502A1 (en) * 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2020036852A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
WO2020112868A1 (en) * 2018-11-30 2020-06-04 Aileron Therapeutics, Inc. Combination therapy of peptidomimetic macrocycles
EP3927344A4 (en) * 2018-12-11 2023-01-18 Kartos Therapeutics METHODS AND COMPOSITIONS FOR THE TREATMENT OF AN EYE CONDITION
CN109731104A (zh) * 2018-12-29 2019-05-10 苏州明基医院有限公司 一种多肽-稀土材料递送系统及制备方法和应用
EP3938051A4 (en) * 2019-03-15 2022-12-07 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF
US20220184087A1 (en) * 2019-03-28 2022-06-16 The Penn State Research Foundation Methods and compositions relating to treatment of cancer
CN118908962A (zh) 2019-05-06 2024-11-08 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
WO2021202961A1 (en) * 2020-04-02 2021-10-07 United States As Represented By Dept Of Veterans Affairs Methods of treating immunotherapy resistant metastatic melanoma
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
US11938124B2 (en) 2020-06-24 2024-03-26 Pmv Pharmaceuticals, Inc. Combination therapy for treatment of cancer
CN111825621A (zh) * 2020-07-22 2020-10-27 天津理工大学 一种奥拉帕尼与丙二酸的共晶及其制备方法
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
CN115137731B (zh) * 2022-05-19 2023-11-21 上海交通大学医学院附属新华医院 Flt3抑制剂及其药学上可接受的盐在制备治疗皮肤t细胞淋巴瘤药物中的应用
CN120077047A (zh) * 2022-10-21 2025-05-30 正大天晴药业集团股份有限公司 大环类化合物及其医药用途
GB202219576D0 (en) * 2022-12-22 2023-02-08 Univ Court Univ Of Glasgow Polypeptides
AU2024361979A1 (en) * 2023-10-20 2026-03-05 Alkermes, Inc. Compound for use in treating narcolepsy
WO2025096608A1 (en) * 2023-10-31 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Egfr covalent inhibition with macrocycles

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5364851A (en) 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
WO2005118620A2 (en) 2004-05-27 2005-12-15 New York University Methods for preparing internally constraied peptides and peptidomimetics
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US7932397B2 (en) 2006-11-22 2011-04-26 Massachusetts Institute Of Technology Olefin metathesis catalysts and related methods
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
BRPI0906685A2 (pt) 2008-01-25 2016-10-11 Massachusetts Inst Technology catalisadores para reações de metátese incluindo metátese de olefina enantiosseletiva, e métodos relacionados
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
EP2352507A4 (en) * 2008-11-24 2012-04-25 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
EP2534140B1 (en) 2010-02-08 2018-04-11 Trustees of Boston College Efficient methods for z- or cis-selective cross-metathesis
KR20170058446A (ko) * 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック, インコーポレイテッド Pd−1軸結合アンタゴニストとmek阻害剤を使用する癌の治療方法
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20150011728A1 (en) * 2012-02-22 2015-01-08 New York University Reversibly crosslinked helical hydrogen bond surrogate macrocycles
PT3077004T (pt) * 2013-12-05 2020-04-16 Hoffmann La Roche Novo tratamento de combinação para a leucemia mieloide aguda (lma)
WO2016049359A1 (en) * 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
SG11201702175YA (en) * 2014-09-24 2017-04-27 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
US10253067B2 (en) * 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Similar Documents

Publication Publication Date Title
JP6971970B2 (ja) ペプチド模倣大環状分子およびその使用
JP2018536621A5 (https=)
CN109414470A (zh) 用于拟肽大环化合物的伴随诊断工具
US11091522B2 (en) Peptidomimetic macrocycles and uses thereof
JP2018516844A (ja) ペプチド模倣大環状分子およびその使用
CN106999541A (zh) 拟肽大环化合物及其用途
JP2020519595A (ja) ペプチド模倣大環状分子およびその使用
CN114173878A (zh) 拟肽大环化合物及其用途
WO2020112868A1 (en) Combination therapy of peptidomimetic macrocycles
HK40043424A (en) Peptidomimetic macrocycles and uses thereof